Pharmaceutical stocks likely pick up in coming quarters
Published: 2004-10-06 07:00:00
Updated: 2004-10-06 07:00:00
Pharmaceutical stocks will likely get a boost in the coming quarters on their defensive nature and expectations for visible outcomes of R&D new drug projects, bolstered by potential sales of generics over Novarsc and Amaryl, analysts said.
A pharmaceutical report, released by Hanyang Securitie...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
